Nicholas J. Valeriani
Known title: DirectorCIK: 0001263149
Nicholas J. Valeriani's purchase track record
Nicholas J. Valeriani has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2021 | EW | $168K | -8.0% | -15.4% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| EW | ▲ Buy | Grant | 5,127 | $0 | 5/8/2026 | View on chart |
| EW | ▲ Buy | Grant | 5,564 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Grant | 4,818 | $0 | 5/8/2024 | View on chart |
| EW | ▲ Buy | Grant | 2,803 | $0 | 5/12/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,300 | $0 | 5/4/2022 | View on chart |
| EW | ▲ Buy | Open Market | 1,500 | $168K | 11/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.